Ph 3 STELLAR clinical study results showing clinically meaningful benefits with eflornithine + lomustine in patients with grade 3 astrocytoma

“For 30 years, SNO has been at the forefront of neuro-oncology, driving discovery and improving patient care, which is why we are excited to have these encouraging results from the STELLAR Study presented at this meeting,” said Jason Levin, President and Chief Executive Officer at Orbus. “In patients with recurrent WHO 2021 grade 3 IDH-mutant astrocytoma, eflornithine not only improved overall survival but, as determined by a blinded independent central review, improved progression-free survival as well. I believe these data, while taken from a subset analysis, represent one of the first meaningful advances for a patient population in which outcomes have been poor for years.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib